Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery

  • STATUS
    Recruiting
  • participants needed
    43
  • sponsor
    University Hospitals Cleveland Medical Center
Updated on 16 February 2024
opioid
opioid use
NSAID
postoperative pain
analgesia
pain relieving
analgesics
oxycodone
nausea
vomiting
immunomodulators
injuries
narcotics
abuse
drug abuse
somnolence
constipation
ketorolac
drugs of abuse
vomit
ambulatory surgery
adjuvant
meniscus tear, tibial

Summary

The utilization of arthroscopic surgery to treat meniscus injuries has continued to increase in recent years, partly due to a younger, more active population, and improved technology and technique. However, pain management in the post-operative period is critical to the ability to perform this procedure as an outpatient surgery. Traditionally, oral narcotic agents have been the preferred analgesic postoperatively in orthopaedic surgery. However, these agents are associated with several side effects, including nausea/vomiting, constipation, and somnolence. In addition, opioid agents have a significant potential for abuse in comparison to non-narcotic analgesics. In light of the rising opioid epidemic and nationwide initiatives to limit narcotic usage, surgeons must explore alternate pain modalities in the acute postoperative period. Ketorolac is a non-steroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory properties.1 Multiple prior studies have examined the beneficial effect of oral and intravenous (IV) ketorolac as an analgesic in the postoperative period,1-3 including arthroscopic meniscus surgery. However, the beneficial effects of this agent following arthroscopic meniscus surgery have not been extensively described.

Details
Condition Postoperative Complication, Postoperative pain, Opioid Use, Meniscus Tear, Tibial, Ketorolac Adverse Reaction
Age 18years - 89years
Treatment Ketorolac, Oxycodone-Acetaminophen
Clinical Study IdentifierNCT04246541
SponsorUniversity Hospitals Cleveland Medical Center
Last Modified on16 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients between 18 and 89 years of age
Patients undergoing primary arthroscopic meniscus surgery

Exclusion Criteria

Patients age less than 18 or greater than 89 years
Illiterate or non-English speaking patients
Patients with contraindications to ketorolac
History of drug or alcohol abuse
Chronic use of analgesic or psychotropic drugs
Clear my responses

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.